Invention Grant
- Patent Title: Mutant of adeno-associated virus (AAV) capsid protein
-
Application No.: US16481159Application Date: 2018-01-29
-
Publication No.: US11028131B2Publication Date: 2021-06-08
- Inventor: Takashi Okada , Hironori Okada , Hiromi Kinoh , Tatsuji Enoki , Toshikazu Nishie , Junichi Mineno
- Applicant: NIPPON MEDICAL SCHOOL FOUNDATION , NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY , TAKARA BIO INC.
- Applicant Address: JP Tokyo; JP Tokyo; JP Shiga
- Assignee: NIPPON MEDICAL SCHOOL FOUNDATION,NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY,TAKARA BIO INC.
- Current Assignee: NIPPON MEDICAL SCHOOL FOUNDATION,NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY,TAKARA BIO INC.
- Current Assignee Address: JP Tokyo; JP Tokyo; JP Shiga
- Agency: Wenderoth, Lind & Ponack, L.L.P.
- Priority: JPJP2017-014377 20170130
- International Application: PCT/JP2018/002680 WO 20180129
- International Announcement: WO2018/139634 WO 20180802
- Main IPC: C12N7/00
- IPC: C12N7/00 ; C12N15/00 ; C07K14/005 ; C12N15/85
Abstract:
The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
Public/Granted literature
- US20200002384A1 MUTANT OF ADENO-ASSOCIATED VIRUS (AAV) CAPSID PROTEIN Public/Granted day:2020-01-02
Information query
